The Outpatient studies we are currently recruiting for are as follows (Summer 2008):

Asthma

Protocol Name:  The Study of Acid Reflux in Children with Asthma
Sponsor: ALA- ACRC / NIH
PI:  John Mastronarde, MD / Jonathan Parsons, MD
Coordinator: David Cosmar
Synopsis:  Study to see if treating adolescent asthmatics with Prevacid improves asthma control.

Protocol Name:  The Asthma Registry for Contact and Possible Participation in a Future Asthma Research Study
Sponsor:  Pulmonary  Division/ OSU Asthma Center
PI:  John Mastronarde, MD / Jonathan Parsons, MD
Coordinator: David Cosmar
Synopsis:  Asthma registry for patients diagnosed with asthma who may be eligible for future studies.

Protocol Name: Mechanisms of exercise induced bronchospasm
Sponsor: OSU Asthma Center/NIH
PI:  Jonathan Parsons, MD/ John Mastronarde, MD
Coordinator: David Cosmar 
Synopsis:    We plan on comparing markers of inflammation in asthmatic participants with and without EIB at baseline and after bronchoprovocation with eucapnic voluntary hyperventilation testing (EVH).

Protocol Name: Micro RNA signatures in acute asthma exacerbations
Sponsor: PulmonaryDivision/OSU Asthma Center
PI:   Clay Marsh, MD; John Mastronarde, MD ; Melissa Hunter, PhD 
Coordinator: David Cosmar
Synopsis:  This is a non-randomized, cohort study of the patterns of microvesicles in the serum of participants with atopic and non-atopic asthma.

COPD/Emphysema

Protocol Name:  Functional Proteomics of Alveolar Macrophages
Sponsor:  NIH
PI:  Philip Diaz, MD & Haifung Wu, MD
Coordinator: David Cosmar; Sharon Cheung
Synopsis: Sstudy to explore Alveolar Microphage pathogenic pathways and genetic contributions in the development of COPD between smokers, non-smokers, and controls.

Protocol Name: Smoking Cessation and the natural history of HIV-associated emphysema
Sponsor: NIH
PI:  Philip Diaz, MD
Coordinator:  Karen Martin
Synopsis: The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.

Protocol Name: Human Immunodeficiency Virus and Emphysema Study
Sponsor: NIH
PI:  Philip Diaz, MD
Coordinator:  Karen Martin
Synopsis: To define the changes and physiologic mechanisms related to the progression of emphysema in subjects who are HIV positive.  In addition this study is comparing the alveolar macrophage proteomes in both HIV – and HIV + subjects to get a better picture of the development of HIV associated emphysema.

Interstial Lung Disease/IPF

Protocol Name: Behavioral Stress, Inflammation and Chronic Lung Disease
Sponsor: Pulmonary Division/Psychiatry Department
PI:  Charles Emery, PhD/ Clay Marsh, MD / Philip Diaz, MD
Coordinator: Robin Brookens
Synopsis:  To examine the relationship between behavioral stress, inflammation and important outcomes in patients with chronic lung disease.

Pulmonary Hypertension

Protocol Name: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension - A multicenter, double-blind, randomized, placebo-controlled, parallel group, prospective, event driven Phase IV study
Sponsor: Actelion / Paraexel
PI:  Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis:  The purpose of this study is to evaluate how safe and how effective bosentan is in combination with sildenafil.  The combination use will be compared to subjects receiving sildenafil only.  Potential subjects will be patients using sildenafil for the treatment of pulmonary arterial hypertension (PAH) who still have symptoms.

Protocol Name:  A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension
Sponsor: United
PI:  Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis:  The purpose of this research study is to determine if UT-15C SR will help control the symptoms of PAH, and to determine if UT-15C SR is safe when it is added to other currently prescribed oral PAH therapies.

Protocol Name:  A 12-Week, International, Multicenter, Double Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT 15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension
Sponsor: United
PI:  Namita Sood, MD
Coordinator:  Sharon Cheung
Synopsis:  The purpose of this research study is to determine if UT 15C SR will help control the symptoms of PAH and determine if it is safe.

Transplantation

Protocol Name: Pulmonary Complications of Hematopoietic Stem Cell Transplantation  (BMT)
Sponsor: NIH
PI: Karen Wood, MD
Coordinator: Anita Kapil
Synopsis: Observational Study.  Subject population consists of patients scheduled to undergo hematopoietic stem cell transplantation at the Ohio State University. No active treatment outside of routine clinical care is involved to determine factors contributing to the development of pulmonary disease.  Study visits consist of protocol related blood draws, questionnaires, and Spirometry/PFT’s.

Protocol Name: Lung Transplantation Specimen Repository
PI:  David Nunley, MD
Coordinator: Pulmonary Division
Synopsis: Lung tissue will be examined to look at biological processes leading to lung disease.

Sarcoidosis

Protocol Name: Stromal Gene Expression during Pulmonary Sarcoidosis 
Sponsor: Pulmonary Division
PI:  Elliot Crouser, MD
Coordinator:
Synopsis: A small amount of tissue sample is analyzed for the hereditary material (genes) that may be the cause of sarcoidosis.